DL-3-n-butylphthalide

Phase 3Small molecule

FFirst Affiliated Hospital Xi'an Jiaotong University

DL-3-n-butylphthalide is one of 53 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentNot yet recruiting

Cognitive ImpairmentPhase 3

Not yet recruiting

Competition

Competitive Landscape

72 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

10 2

Exelon

Novartis

Approved

5 3

Ritalin

Novartis

Approved

3 4

Aldactone

Pfizer

Approved

1 5

Cymbalta

Jazz Pharmaceuticals

Approved

1 6

Marinol

Brintellix

Intropin

Glucophage

3 10

Lithobid

SSolvay Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Cognitive Impairment

NCT06508671

Clinical

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

Completed·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT02711683·92 enrolled

Ischemic stroke1 trial

Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Completed·SShanghai 6th People's Hospital·Phase 1/2·NCT02149875·84 enrolled

Cognitive impairment1 trial

Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment

Not yet recruiting·FFirst Hospital of China Medical University·Phase 4·NCT06508671·100 enrolled

Moyamoya disease1 trial

NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

Unknown status·Yyuanli Zhao·Phase 3·NCT04205578·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for DL-3-n-butylphthalide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DL-3-n-butylphthalide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DL-3-n-butylphthalide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital Xi'an Jiaotong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFirst Affiliated Hospital Xi'an Jiaotong University

DL-3-n-butylphthalide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

Ischemic stroke1 trial

Cognitive impairment1 trial

Moyamoya disease1 trial

References

Drug Info

Quick Facts

Related News